No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study

Yoann Zadro; Margaux Lafaurie; Agnès Sommet; Maryse Lapeyre-Mestre; Guillaume Moulis

doi:10.3324/haematol.2025.300199

Open access journal of the Ferrata-Storti Foundation, a non-profit organization

Letters to the Editor

No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study

Yoann Zadro
Margaux Lafaurie
Agnès Sommet
Maryse Lapeyre-Mestre
Guillaume Moulis

Clinical Investigation Center 1436, Toulouse University Hospital, Toulouse University, France; Department of Internal Medicine, referral center for autoimmune cytopenia, Toulouse University Hospital, Toulouse University

Clinical Investigation Center 1436, Toulouse University Hospital, Toulouse University, France; Department of Clinical Pharmacology, Toulouse University Hospital, Toulouse University

Haematologica Early view Mar 12, 2026 https://doi.org/10.3324/haematol.2025.300199

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor

DOI

https://doi.org/10.3324/haematol.2025.300199

Published

2026-03-12

Published By

Ferrata Storti Foundation, Pavia, Italy

Print ISSN

0390-6078

Online ISSN

1592-8721

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

No Data Yet

Statistics from Altmetric.com

No Data

No increased risk of acute myeloid leukemia in adults with primary immune thrombocytopenia treated with thrombopoietin receptor agonists: a French nationwide population-based study

Abstract

Figures & Tables

Article Information

Article Usage

Statistics from Altmetric.com

Download Citation

Navigate

For Authors

For Reviewers

For Advertisers

Education

Privacy

More